Hospital Clínico Universitario de Valencia
Valencia, Spain
37 recruiting
Showing 1–20 of 55 trials
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled339 locationsNCT05633654
Recruiting
Phase 3
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Urothelial CarcinomaUpper Urinary Tract Urothelial Carcinoma
UroGen Pharma Ltd.70 enrolled52 locationsNCT06774131
Recruiting
Phase 1Phase 2
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Advanced Solid Tumors
Pyxis Oncology, Inc220 enrolled19 locationsNCT06795412
Recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Metastatic Colorectal Cancer
Hoffmann-La Roche542 enrolled76 locationsNCT04929223
Recruiting
Phase 2
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Breast Cancer
Hoffmann-La Roche60 enrolled30 locationsNCT07054190
Recruiting
Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Gilead Sciences695 enrolled205 locationsNCT06801834
Recruiting
Phase 3
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
Leiomyosarcoma
PharmaMar450 enrolled97 locationsNCT06088290
Recruiting
Phase 2
Study of Lacutamab in Peripheral T-cell Lymphoma
Relapse/RecurrencePeripheral T Cell Lymphoma
The Lymphoma Academic Research Organisation56 enrolled64 locationsNCT04984837
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Non-small Cell Lung CancerKRAS G12C Lung Cancer
Hoffmann-La Roche600 enrolled217 locationsNCT06793215
Recruiting
Phase 4
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
Breast Cancer
Hoffmann-La Roche320 enrolled28 locationsNCT06274515
Recruiting
Phase 2
CRF2 Agonist for the Treatment of Worsening Heart Failure
Worsening Heart Failure
Corteria Pharmaceuticals300 enrolled55 locationsNCT06815471
Recruiting
Phase 2
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
Advanced Breast CancerHormone Receptor-Positive Breast CarcinomaAdvanced Breast Carcinoma
MedSIR200 enrolled56 locationsNCT06486883
Recruiting
A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
Breast Neoplasms
Spanish Breast Cancer Research Group1,867 enrolled40 locationsNCT02819882
Recruiting
Phase 3
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Low Grade Serous Ovarian Cancer
Verastem, Inc.270 enrolled106 locationsNCT06072781
Recruiting
Phase 3
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
HER2-negative Breast CancerAdvanced Breast CancerER Positive Breast Cancer+1 more
MedSIR240 enrolled99 locationsNCT06382948
Recruiting
Phase 4
Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome
Elderly (People Aged 65 or More)Iron Deficienciesacute coronary syndromes (ACS)
Fundación para la Investigación del Hospital Clínico de Valencia538 enrolled9 locationsNCT07476859
Recruiting
Phase 3
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Breast Cancer
Greenwich LifeSciences, Inc.750 enrolled166 locationsNCT05232916
Recruiting
Phase 1
A Study of PYX-201 in Advanced Solid Tumors
Advanced Solid TumorSolid Tumor
Pyxis Oncology, Inc330 enrolled29 locationsNCT05720117
Recruiting
Not Applicable
Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T Therapy
Hematologic Cancer
Instituto de Investigacion Sanitaria INCLIVA100 enrolled2 locationsNCT07173166
Recruiting
Phase 2
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
Breast Cancer
MedSIR976 enrolled41 locationsNCT05708235